IFNG and Primary hemophagocytic lymphohistiocytosis: Recently, in the United States, a recombinant IFN‐γ blocking antibody (Emapalumab) was approved for patients with primary hemophagocytic lymphohistiocytosis (Al‐Salama, 2019).